GINKGO BIOWORKS HOLDINGS, INC. (DNABW)

Every figure this model derived for DNABW, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 4,557,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 339,953,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 332,535,000 AssetsCurrent 2026-06-30
current liabilities 72,740,000 LiabilitiesCurrent 2026-06-30
equity 420,284,000 StockholdersEquity 2026-06-30
interest expense 0 InterestExpenseNonoperating 2025-12-31
ocf -170,243,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 111,863,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 68,805,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up DNABW on one particular measure came for.

RatioValue
cash operating margin-150.05
current ratio5.59
current ratio reported4.57
deferred revenue growth-53.29
dilution pct6.87
fcf margin-156.26
growth cv2.34
operating margin-259.86
owner earnings margin-217.77
revenue growth-46.8
revenue growth per share-50.22
roic-285.8
rpo growth10.68
rule of 40-306.66
sbc pct revenue61.51

What to be careful about

What this model itself distrusts about DNABW's figures. Written by the derivation as it ran, not added afterwards.